礼来公司的减肥药 Zepbound（tirzepatide）在后期试验中使睡眠呼吸暂停发作次数减少了高达 63%。 Eli Lilly's weight-loss drug Zepbound (tirzepatide) reduces sleep apnea episodes by up to 63% in late-stage trials.

礼来公司的减肥药 Zepbound 已被证明可以减少睡眠呼吸暂停发作，为其扩大使用铺平了道路。 Eli Lilly's weight-loss drug Zepbound has been proven to reduce sleep apnea episodes, paving the way for its expanded use. GLP-1 药物在两次后期试验中将不规则呼吸发作的频率降低了 63%。 The GLP-1 drug reduced the frequency of irregular breathing episodes by up to 63% across two late-stage trials. Zepbound，也称为 tirzepatide，已显示出除糖尿病和减肥之外的潜在医疗益处，试验结果为越来越多的相关临床证据增添了新内容。 Zepbound, also known as tirzepatide, has shown potential medical benefits beyond diabetes and weight loss, and the trial results add to a growing body of related clinical evidence.